PriceTargets.com logo

NASDAQ:SPRB - Spruce Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.75
  • Forecasted Upside: 75.23 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$19.26 As of 03/8/2021 01:00 AM ET
▲ +0.98 (5.36%)
1 month | 3 months | 12 months
Get New Spruce Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPRB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.75
▲ +75.23% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $33.75, with a high forecast of $44.00 and a low forecast of $28.00. The average price target represents a 75.23% upside from the last price of $19.26.
Buy
The current consensus among 4 investment analysts is to buy stock in Spruce Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2020SVB LeerinkInitiated CoverageOutperform$35.00High
i
Rating by J. Schwartz at SVB Leerink LLC
11/3/2020Royal Bank of CanadaInitiated CoverageOutperform$28.00High
i
11/3/2020Credit Suisse GroupInitiated CoverageOutperform$28.00High
i
11/3/2020CowenInitiated CoverageOutperform$44.00High
i
(Data available from 3/8/2016 forward)
Spruce Biosciences logo
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Read More

Today's Range

Now: $19.26
$18.39
$20.14

50 Day Range

MA: $20.84
$18.14
$23.80

52 Week Range

Now: $19.26
$15.12
$35.60

Volume

17,881 shs

Average Volume

33,663 shs

Market Capitalization

$447.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Spruce Biosciences?

The following Wall Street analysts have issued stock ratings on Spruce Biosciences in the last year: Cowen Inc, Credit Suisse Group AG, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for SPRB.

What is the current price target for Spruce Biosciences?

4 Wall Street analysts have set twelve-month price targets for Spruce Biosciences in the last year. Their average twelve-month price target is $33.75, suggesting a possible upside of 84.6%. Cowen Inc has the highest price target set, predicting SPRB will reach $44.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $28.00 for Spruce Biosciences in the next year.
View the latest price targets for SPRB.

What is the current consensus analyst rating for Spruce Biosciences?

Spruce Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPRB will outperform the market and that investors should add to their positions of Spruce Biosciences.
View the latest ratings for SPRB.

What other companies compete with Spruce Biosciences?

Other companies that are similar to Spruce Biosciences include Aurinia Pharmaceuticals, Ironwood Pharmaceuticals, Organogenesis, Endo International, Heron Therapeutics, Shattuck Labs, PMV Pharmaceuticals, ADC Therapeutics, Arcutis Biotherapeutics, Kronos Bio, Kiniksa Pharmaceuticals, Zymeworks, Amneal Pharmaceuticals, COMPASS Pathways and MacroGenics.

How do I contact Spruce Biosciences' investor relations team?

The company's listed phone number is 415-294-1687 and its investor relations email address is [email protected] The official website for Spruce Biosciences is www.sprucebiosciences.com.